Cinemark Holdings, Inc. (CNK): what the price requires

At today's price, Cinemark Holdings, Inc. (CNK) is priced for +8.4% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-19 · Source: https://boothcheck.com/report/CNK

Headline

FieldValue
TickerCNK
CompanyCinemark Holdings, Inc.
Current price$29.26/sh
CompositionAdmissions Revenue 50% / Concession Revenue 39% / Screen advertising, screen rental and promotional revenue 5% / Other Revenue 6%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin (mid-cycle)7.8%
Implied growth8.4%
Multiple paid28x mid-cycle operating income

Solve inputs: computed at a 7% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~9.1pp (computed at the 7% minimum rate; the CAPM rate 2.9% sits below it).

Reconcile: at the x-ray's 9.3% required return this reads ~5.4 years; the models below use their own rates.

How unusual the bet is: within-range (limited comparison data)

ReferenceValue
vs own history+0.59σ
implied end-window share0%

Valuation X-Ray

The price is supported by earnings-power value, while relative-multiple lands below the price. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.45x4expensive
Earnings0.70x1justifies
Relative2.44x1expensive
Growth—0—

Families that justify the price: Earnings Families that call it expensive: Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 4.8%); the inversion above states its own rate.

Per-Model Detail (n=6)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$0.00—noNegative/zero FCF — equity value floored at $0
DCF Exit MultipleGrowth$0.00—noNegative/zero FCF or EBITDA — equity value floored at $0
Relative ValuationRelative$11.972.44xyesP/E 14x (static sector reference · 2026-04), scenarios: 11.6x / 14.0x / 16.4x (bear / base = reference held flat / bull), EV/EBITDA 15.75x
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$16.091.82xyesBV/sh $1.70, ROE (TTM) 87.6%, ke 9.3%
Two-Stage Excess ReturnAsset$91.020.32xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$24.021.22xnoRev $3.2B, growth 9% (input: historical growth; tapered), Terminal P/S: 0.9x / 1.0x / 1.2x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$33.610.87xnoEPS $1.30, growth 26% (input: historical EPS growth), PEG=0.76 (Undervalued)
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings$0.012926.00xnoNormalized EBIT (5y avg op income, one-time charges added back) $0.01B × (1−21%) / WACC 4.8% → EPV (no growth)
Residual IncomeAsset$27.011.08xyesBV $1.70 + 5yr PV of (ROE (TTM) 87.6% − Kₑ 9.3%) × BV; BV grows 8.8%/yr
Graham NumberAsset$7.054.15xyes√(22.5 × EPS $1.30 × BVPS $1.70) — Graham's conservative floor
EV/EBITDA RelativeRelative$0.012926.00xyesEBITDA $0.20B × sector EV/EBITDA 9.0x (excluded from median)
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings$41.950.70xyesEPS $1.30 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative$56.100.52xnoRevenue $3.22B × sector P/S 2.0x
PEG Fair ValueRelative$48.750.60xnoEPS $1.30 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings YieldEarnings$14.052.08xnoEPS $1.30 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net debt$3.6b
Share count CAGR (buyback)-0.7%
Burning cashno

Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.

Operating profit is negative or near zero and there is no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so interest coverage cannot be computed honestly.

Bullet Takeaways

Bull Case

Read Cinemark at its stage and the trough numbers stop being alarming and start being the setup. This is a mature theater operator working its way back from the pandemic shock, and the recovery is now visible in the results rather than just the narrative. First-quarter revenue grew 18.9% to $643.1 million, attendance reached 39.0 million, and adjusted EBITDA more than doubled to $88.5 million with margin expanding over 700 basis points, narrowing the seasonally weak first-quarter net loss to just $6.4 million from $38.9 million a year earlier. The right way to read a cyclical recovery is through normalized earnings, not the trough quarter, and on the company's own through-the-cycle margins the business is solidly profitable; the depressed trailing figures understate the earning power the recovery is restoring.

The economics of the model are better than the box-office headlines suggest, because the concession stand is where the money is made. Nearly 40% of revenue comes from food and beverage at very high margins, and the first quarter set a record for concession sales as per-customer spending rose. Cinemark has leaned into the levers that drive that monetization, loyalty programs, premium formats, and showtime optimization, and it held its market share flat against a tough comparison. A theater that grows revenue per visit faster than attendance is improving the quality of its earnings, not just riding the slate.

The balance sheet has been repaired, which is what lets the bull case breathe. Cinemark extinguished more than $700 million of pandemic-era debt, brought its net leverage down to about 2.6 times EBITDA, and crucially reinstated its dividend at $0.09 a quarter, a management decision that signals confidence the recovery is durable rather than fragile. With a healthier balance sheet and a strong 2026 film slate ahead, management guides to roughly 10% domestic box-office growth driving revenue up about 12% and EBITDA up about 25%. The operating leverage of a theater, where incremental ticket and concession revenue rides on a largely fixed cost base, is what turns a good slate into outsized profit growth. The bull case is a deleveraged, well-run operator at the front of a box-office recovery with a strong content year ahead.

Bear Case

The external variable with the most leverage on Cinemark is one it does not control at all: the film slate that the studios choose to make and release. A theater chain is a fixed-cost host waiting for content, and a year of weak or delayed releases empties the seats regardless of how well the theaters are run. The 2026 outlook depends on a strong slate materializing on schedule, and Hollywood's production and release timing has been volatile since the pandemic and the labor disruptions that followed. Management even flagged that the crowded summer and year-end slates could create capacity constraints, which is a reminder that the business is hostage to a release calendar set by others.

The structural threat is the slow erosion of the theatrical window. Streaming has compressed the time between a film's theatrical release and its availability at home, and shortened windows for smaller films continue to pressure the long-term sustainability of the box office. The risk is not that theaters vanish overnight; it is that the mid-budget film, once a reliable driver of attendance between the blockbusters, increasingly skips theaters or arrives at home within weeks. That hollows out the calendar between tentpoles and makes the whole industry more dependent on a handful of franchise releases, which raises the variance of any given year. A business priced for steady recovery is exposed to a structural drift that does not reverse.

The leverage magnifies that exposure. Even after extinguishing more than $700 million of debt, Cinemark still carries net debt near $1.9 billion, and interest coverage on its trough earnings is thin. The company's recent history includes negative retained earnings and balance-sheet stress signals that flag financial fragility, the legacy of the pandemic years. On normalized mid-cycle earnings the leverage is manageable at about 2.6 times EBITDA, but a single weak box-office year would pressure the coverage quickly, and the equity, sitting on a thin book value, is the piece that absorbs it. The valuation already credits the recovery: the price sits well above where the asset-based and peer-multiple methods land, so a buyer is paying up for a continued rebound. The bear case is that a levered, fixed-cost host of other people's content, priced for a strong slate to keep coming, has little cushion if the calendar disappoints or the theatrical window keeps narrowing.

Valuation

Cinemark has to be valued on normalized earnings, because the trailing quarter is depressed by the cycle and reading it literally would mislead. The engine does exactly that: it prices the company on its own through-the-cycle margins rather than the trough, and on that mid-cycle basis the price implies operating growth of about 10.4% a year for five years. That pace is within what Cinemark has recently delivered as it recovers, so the demanding part is the duration, the assumption that the rebound sustains, rather than the rate itself. Worked backward, the overall bet reads as within range, broadly consistent with plausible growth, which is a more forgiving verdict than the trough numbers alone would suggest.

The method families split in the way they do for a recovering cyclical with a thin balance sheet. The relative-multiple methods, on a blended earnings multiple, land below the price, reading the stock as expensive against its cohort. The asset-based methods also land below, because Cinemark's book value per share is very thin, the residue of years of pandemic losses, which makes book-based fair values low and return-on-equity figures distorted to the point of being uninformative. The earnings-power methods come closest to the price. The pattern is a name supported by its normalized earnings power but expensive on its assets and peer multiples, which is to say the price is paying for the recovery to continue, not for a discount to today's depressed fundamentals.

Solvency is the binding constraint, and it is much improved but not yet comfortable. Net debt sits near $1.9 billion, and on the company's reported EBITDA the leverage is about 2.6 times, a level the extinguishment of more than $700 million of pandemic debt made possible and that supported the dividend reinstatement. But interest coverage on trough earnings is thin, and the distress signals in the trailing accounts, negative retained earnings among them, are the scar tissue of the pandemic. The decisive variable is the box-office cycle: on a strong slate the normalized earnings the valuation rests on are real and the leverage is serviceable; on a weak one the coverage tightens fast. The price has chosen to believe the recovery holds and the 2026 slate delivers, and the valuation rests on that content calendar more than on anything inside the company's control.

Catalysts

The recovery trajectory is the catalyst, and the first quarter confirmed it. Revenue grew 18.9% to $643.1 million, attendance reached 39.0 million, adjusted EBITDA more than doubled to $88.5 million with margin up over 700 basis points, and the seasonal net loss narrowed sharply to $6.4 million, with GAAP earnings of negative $0.06 a share beating expectations. Concession sales set a record on higher per-customer spending. The quarterly attendance and per-cap trends are the cleanest read on whether the rebound is sustaining.

The 2026 film slate is the catalyst the company is betting on. Management guides to roughly 10% domestic box-office growth in 2026, expected to lift revenue about 12% and EBITDA about 25%, while flagging that the crowded summer and year-end slates could create capacity constraints. Because the slate is set by the studios, the actual release calendar and the performance of the tentpole films are the external events that determine whether that guidance is met.

Capital structure and return are the confirming catalysts. Cinemark extinguished more than $700 million of pandemic-era debt, brought net leverage to about 2.6 times, and reinstated its quarterly dividend at $0.09 a share, a statement of confidence in the recovery. Analyst sentiment has turned bullish, with a median price target around $35 in a range from the low $20s to the high $30s, and Benchmark among the firms raising targets on strong box-office trends. The structural watch item is the theatrical window: any further compression for mid-budget films would be the development that undercuts the long-term box-office base the valuation assumes.

Peer Cohorts (Per Segment, With Filing Citations)

U.S. Reportable Segment / International Reportable Segment (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Q1 2026 results · Q1 2026 results and guidance · company disclosures, 2026 · analyst notes, 2026

View the full interactive CNK report on boothcheck